FEATURED

The contract includes the supply of a Proteus®ONE system and a Quality Assurance package from IBA Dosimetry. Proteus®ONE is the market leading compact proton therapy system, upgradable over time to continue to offer the latest technology to IBA users. The system will also include DynamicARC®[2] beam delivery capabilities, once this feature has received regulatory clearance.

Luna advises the new collaboration will start taking appointments in February 2025, and patients seeking care will receive safe, high-quality PT conveniently delivered to their homes.

Masonicare at Ashlar Village earned Purple Flag accreditation in 2021, which helped establish it as a leader in dementia care. Purple Flag has seen tremendous growth nationwide since then, with 32 accredited communities now flying the Purple Flag.

"AI holds the potential to revolutionize patient care, but its progress has been stalled by fragmented systems and the inability to scale effectively," said Demetri Giannikopoulos, Chief Transformation Officer, Aidoc. "The BRIDGE guideline will focus on breaking down these barriers, offering a powerful, evidence-based framework that health systems can rely on not just adopt AI but to help scale it across their operations. This will drive both operational efficiency and significantly better outcomes for patients and clinicians alike."

”We aim to be a leading global research and development company. This is a crucial component in our IPR portfolio and underscores our commitment to an ambitious IPR and market strategy”, says Jean Lycke at Mucocort.

"By embracing AI in healthcare, we are transforming how care is delivered and setting a new standard for patient-centered, personalized, and efficient care," said Nordic Chief Medical Officer Craig Joseph, MD. "Our partnership with BeeKeeperAI and the integration of RightAI into the EHR allows us to introduce AI models that create real-world impact and drive better patient outcomes."

Jakes Jordaan, CEO at TriCelX: “With the guidance of our Military Advisory Board, which includes Gen. Lance L. Smith and Brigadier Gen. Mark T. Kimmitt, our team is developing a proprietary biological medical countermeasures cell processing platform -- to produce native, non-expanded biologics -- to help our warriors facing unique threats such as Acute Radiation Syndrome, Traumatic Brain Injury and battlefield wounds.”

The OrganOx metra® System utilizes normothermic machine perfusion, or NMP, to circulate oxygenated blood, medications, and nutrients to donated organs at normal body temperature and near physiological conditions.